Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altheos, a biopharmaceutical company focused on treatments for glaucoma and ocular hypertension, has named Barbara Wirostko as the new chief medical officer of the company.
Subscribe to our email newsletter
Prior to joining Altheos, Wirostko worked with Pfizer as the senior medical director and the glaucoma medical team lead and was responsible for pipeline strategy in glaucoma, overseeing the pediatric development program and Global Medical Affairs Programs for the Xalabrands franchise.
Altheos CEO Henry Hsu said that Barbara’s expertise in glaucoma as a clinician and medical director for drug development make her an ideal fit for the Altheos team as we initiate our clinical program for lead compound, ATS907.
“She brings broad experience covering the spectrum from leading development strategy teams to marketing and reimbursement considerations at the point of care,” Hsu said.